SCHEMBL2578433

SCHEMBL2578433

CC(C)(C)c1cc(N)n(-c2ccc(CO)c(Cl)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 5/20 0.43
PRKCZ Q05513 1/20 0.40
NPC1 O15118 1/20 0.39
PTGS2 P35354 4/20 0.39
MAPK14 Q16539 4/20 0.38
ABL1 P00519 1/20 0.38
ABL2 P42684 1/20 0.38
MAPK8 P45983 1/20 0.38
MAPK11 Q15759 1/20 0.38
CDK8 P49336 1/20 0.37
SRC P12931 1/20 0.36
DDR2 Q16832 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
RECQL P46063 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16284441 0.90 PTGS2 (0.41) TRPV1PRKCZPTGS2MAPK14ABL1
Hydrochloric Acid SCHEMBL16279933 0.88 PTGS2 (0.41) TRPV1PRKCZPTGS2MAPK14ABL1
SCHEMBL13946380 0.83 L3MBTL1 (0.49) PRKCZNPC1MAPK14ABL1ABL2
SCHEMBL4205964 0.82 PRKCZ (0.57) PRKCZNPC1MAPK14ABL1ABL2
SCHEMBL16279774 0.82 TRPV1 (0.41) TRPV1PRKCZPTGS2MAPK14ABL1
SCHEMBL14656366 0.82 PTGS2 (0.42) PTGS2MAPK14MAPK11CDK8SRC
SCHEMBL16279973 0.82 PTGS2 (0.43) TRPV1PTGS2CDK8
SCHEMBL10363266 0.81 RAB9A (0.49) PRKCZNPC1MAPK14MAPK11CDK8
SCHEMBL14688102 0.80 TRPV1 (0.38) TRPV1PRKCZNPC1MAPK14ABL1
SCHEMBL4199674 0.80 PRKCZ (0.48) PRKCZNPC1MAPK14ABL1ABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10358445-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2019-07-23 US disclosed
EP-2556068-B1 P38 MAP KINASE INHIBITORS RESPIVERT LTD (GB) 2019-01-23 EP disclosed
US-20180201611-A1 Respiratory formulations and compounds for use therein RESPIVERT LTD. (GB) 2018-07-19 US disclosed
EP-2582700-B1 RESPIRATORY FORMULATIONS CONTAINING P38 MAPK INHIBITORS RESPIVERT LTD (GB) 2016-11-02 EP disclosed
US-9024041-B2 P38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2015-05-05 US disclosed
US-8933228-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2015-01-13 US disclosed
US-20130156826-A1 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN RESPIVERT LIMITED (GB) 2013-06-20 US disclosed
US-20130040962-A1 P38 MAP Kinase Inhibitors RESPIVERT LTD (GB) 2013-02-14 US disclosed
EP-2556068-A1 P38 MAP KINASE INHIBITORS Respivert Limited (GB) 2013-02-13 EP disclosed
WO-2011124930-A1 P38 MAP KINASE INHIBITORS RESPIVERT LIMITED (GB) 2011-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130156826-A1 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN TSLP, CCL11, RORB TRPV1 1146/4885PRKCZ 4060/4885NPC1 547/4885
US-10358445-B2 Respiratory formulations and compounds for use therein TSLP, CCL11, RORB TRPV1 1146/4885PRKCZ 4060/4885NPC1 547/4885
US-20130040962-A1 P38 MAP Kinase Inhibitors MAPK15, MAPK1, MAP3K15 TRPV1 3593/4885PRKCZ 120/4885NPC1 3262/4885
US-20180201611-A1 Respiratory formulations and compounds for use therein TSLP, CCL11, RORB TRPV1 1146/4885PRKCZ 4060/4885NPC1 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.